Sign in

Private company

Surface Oncology, Inc.

American biological products company based in Cambridge, no longer active2

In its 2023 annual report the company says: “We are a clinical-stage immuno-oncology company focused on using our specialized knowledge of the biological pathways critical to the immunosuppressive tumor microenvironment, or the TME, for the development of next-generation cancer therapies.”55

Last updated Oct 21, 2026.

Overview

  • IndustryBiological Products, (No Diagnostic Substances)2
  • HeadquartersCambridge, United States2
  • Incorporated inDE3
  • Business address50 Hampshire Street, 8Th Floor, Cambridge, Ma 021393
  • Filer category, Emerging growth company3
  • Legal formCorporation2
  • LEI549300FCSG6MNIMFH7382
  • StatusInactive2
  • LEI statusRetired2
  • Registered addressC/O The Corporation Trust Company, 19801 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 55247492

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-206.2%Operating margin4
-212.0%Net margin4
1016.5%Revenue growth, 20224
-68.1%Return on equity4
-$60.0MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Research and development96¢$67.0M
  • Interest4¢$3.1M

Out of $30.0M in revenue.4 The company lost money this year.

Financial statements

Revenue56784$30.0M in 2022+352% since 2016
0$25.0M$50.0M$75.0M$100.0M2016: $6.6M$6.6M20162017: $12.8M$12.8M2017+93%2018: $0$020182019: $0$020192020: $87.6M$87.6M20202021: $2.7M$2.7M2021−97%2022: $30.0M$30.0M2022+1016%
Operating income56784-$61.9M in 2022+244% since 2016
-$100.0M-$50.0M0$50.0M$100.0M2016: -$18.0M-$18.0M20162017: -$46.0M-$46.0M2017+155%2018: -$9.2M-$9.2M2018−80%2019: -$57.4M-$57.4M2019+527%2020: $61.6M$61.6M20202021: -$76.0M-$76.0M20212022: -$61.9M-$61.9M2022−19%
Net income56784-$63.6M in 2022+264% since 2016
-$100.0M-$50.0M0$50.0M$100.0M2016: -$17.5M-$17.5M20162017: -$45.4M-$45.4M2017+160%2018: -$6.6M-$6.6M2018−85%2019: -$54.8M-$54.8M2019+731%2020: $59.3M$59.3M20202021: -$78.5M-$78.5M20212022: -$63.6M-$63.6M2022−19%
Fiscal year2016201720182019202020212022
Revenue$6.6M5$12.8M6$07$08$87.6M4$2.7M4$30.0M4
Research and development$20.5M5$47.8M6$52.5M7$52.1M8$41.0M4$53.6M4$67.0M4
Operating expenses$78.7M4$91.9M4
Operating income-$18.0M5-$46.0M6-$9.2M7-$57.4M8$61.6M4-$76.0M4-$61.9M4
Interest$145.0K8$2.9M4$2.5M4$3.1M4
Income before tax-$78.5M4-$63.6M4
Net income-$17.5M5-$45.4M6-$6.6M7-$54.8M8$59.3M4-$78.5M4-$63.6M4
Earnings per share-$0.337-$1.978$1.674-$1.774-$1.144
Earnings per share (diluted)-$0.337-$1.978$1.574-$1.774-$1.144
Shares (weighted, basic)44.2M shares455.8M shares4
Shares (weighted, diluted)44.2M shares455.8M shares4

Compare Surface Oncology, Inc. with another company

Corporate structure

Surface Oncology, Inc. is part of a group headed by Coherus BioSciences (United States). 2 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Surface Oncology, Inc.

  • ADAR1 Partners, LP Filed SC 13G on Surface Oncology, Inc., latest Jul 20, 2023
  • EcoR1 Capital, LLC Filed SC 13G/A on Surface Oncology, Inc., latest Feb 13, 2023 (2 filings since Mar 14, 2022)
  • ARK Investment Management LLC Filed SC 13G/A on Surface Oncology, Inc., latest Feb 10, 2023 (3 filings since Feb 9, 2022)
  • Atlas Venture Fund IX, L.P. Filed SC 13G/A on Surface Oncology, Inc., latest Jan 31, 2023 (2 filings since Jan 25, 2022)
  • BlackRock Filed SC 13G on Surface Oncology, Inc., latest May 9, 2022 (2 filings since Feb 4, 2022)
  • Eli Lilly and Company Filed SC 13G/A on Surface Oncology, Inc., latest Feb 10, 2022
  • FMR LLC Filed SC 13G/A on Surface Oncology, Inc., latest Feb 9, 2022

Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Surface Oncology, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$14.0M4 Dec 31, 2022$13.4M4 Dec 31, 2021+4.3%
Accumulated depreciation$9.1M4 Dec 31, 2022$7.8M4 Dec 31, 2021+17.6%
Property and equipment, net$4.9M4 Dec 31, 2022$5.7M4 Dec 31, 2021−13.9%
Operating-lease assets (leased space)$24.3M4 Dec 31, 2022$25.9M4 Dec 31, 2021−6.0%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$50.9M4 Dec 31, 2022$56.0M4 Dec 31, 2021−9.2%
Marketable securities, current$73.9M4 Dec 31, 2022$98.1M4 Dec 31, 2021−24.7%
Debt securities available for sale$73.9M4 Dec 31, 2022$98.1M4 Dec 31, 2021−24.7%

Leadership

Who has led Surface Oncology, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Jeff Goater2018–2021

Chief financial officer

  1. Jessica Fees2022–2023
20202025
Board members and other officers (19)

Timeline

  1. Sep 8, 20238-K Completed an acquisition or sale; Listing notice or transfer; Change to shareholders' rights31
  2. Aug 30, 20238-K Other events32
  3. Aug 2, 20238-K Results of operations33
  4. Jul 10, 20238-K Listing notice or transfer34
  5. Jul 3, 20238-K Other events35
  6. Jun 16, 20238-K Entered a material agreement; Ended a material agreement; Exit or restructuring costs36
  7. May 4, 20238-K Results of operations37
  8. Mar 9, 20238-K Results of operations38
  9. Feb 10, 20238-K Executive or director change39
  10. Jan 12, 20238-K Listing notice or transfer40
  11. Nov 2, 20228-K Results of operations; Other events41
  12. Sep 23, 20228-K Entered a material agreement; New debt or obligation42
  13. Apr 18, 2018New chief executive Jeff Goater becomes CEO11
  14. Apr 29, 2014Founded Surface Oncology, Inc. is founded2

Calendar

When it reported results

  1. Aug 2, 2023Reported quarterly or annual results33
  2. May 4, 2023Reported quarterly or annual results37
  3. Mar 9, 2023Reported quarterly or annual results38
  4. Nov 2, 2022Reported quarterly or annual results41
  5. Aug 3, 2022Reported quarterly or annual results43
  6. May 9, 2022Reported quarterly or annual results44
  7. Mar 2, 2022Reported quarterly or annual results45
  8. Nov 4, 2021Reported quarterly or annual results46

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

125 filings to the SEC since October 2021: 3 annual reports, 6 quarterly reports, 21 major events, 52 insider forms, 12 large holders, 31 other. The latest 20:

  1. Sep 18, 202315-12G EDGAR
  2. Sep 12, 2023EFFECT EDGAR
  3. Sep 12, 2023EFFECT EDGAR
  4. Sep 8, 20234 FORM 4 SUBMISSION EDGAR
  5. Sep 8, 20234 FORM 4 SUBMISSION EDGAR
  6. Sep 8, 20234 FORM 4 SUBMISSION EDGAR
  7. Sep 8, 20234 FORM 4 SUBMISSION EDGAR
  8. Sep 8, 20234 FORM 4 SUBMISSION EDGAR
  9. Sep 8, 20234 FORM 4 SUBMISSION EDGAR
  10. Sep 8, 20234 FORM 4 SUBMISSION EDGAR
  11. Sep 8, 20234 FORM 4 SUBMISSION EDGAR
  12. Sep 8, 20234 FORM 4 SUBMISSION EDGAR
  13. Sep 8, 2023S-8 POS EDGAR
  14. Sep 8, 2023S-8 POS EDGAR
  15. Sep 8, 2023S-8 POS EDGAR
  16. Sep 8, 2023S-8 POS EDGAR
  17. Sep 8, 2023S-8 POS EDGAR
  18. Sep 8, 2023S-8 POS EDGAR
  19. Sep 8, 2023POS AM EDGAR
  20. Sep 8, 2023POS AM EDGAR

The 125 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

9 open-market trades by officers, directors and large owners since October 2021: 0 buys and 9 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 1, 2023ONEILL ALISONChief Medical OfficerSale7,042$0.94$6.6KForm 4
Aug 1, 2023Adams ChandraDeputy GCSale3,901$0.94$3.7KForm 4
Aug 1, 2023FEES JESSICAChief Financial OfficerSale9,434$0.94$8.9KForm 4
Aug 1, 2023ROSS ROBERT W.Chief Executive OfficerSale16,713$0.94$15.7KForm 4
Aug 3, 2022RATH HENRY C.Chief Business OfficerSale5,676$1.72$9.8KForm 4
Aug 3, 2022ONEILL ALISONChief Medical OfficerSale4,463$1.72$7.7KForm 4
Aug 3, 2022ROSS ROBERT W.Chief Executive OfficerSale10,594$1.72$18.2KForm 4
Aug 3, 2022FEES JESSICAChief Financial OfficerSale5,980$1.72$10.3KForm 4
Aug 3, 2022Palombella Vito J.Chief Scientific OfficerSale4,463$1.72$7.7KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Surface Oncology, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARSurface Oncology, Inc.1
  • CIK0001718108
  • Filer status<br>emerging growth company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
  • Business address50 Hampshire Street, 8Th Floor, Cambridge, MA 021391
  • Phone617-714-40961
  • Shares outstanding60,824,474 as of Jul 31, 202310
  • Public float$85.4M as of Jun 30, 202254
  • On EDGAR sinceNov 17, 20171
  • Filings406 in all: 4 (142), 8-K (72), 3 (38), SC 13G/A (25), 425 (19), 10-Q (17), SC 13G (16), CORRESP (7)1
    All 34 form types

    DEFA14A (7), S-8 (6), S-8 POS (6), UPLOAD (6), 10-K (5), EFFECT (5), CT ORDER (4), DEF 14A (4), 4/A (3), S-1/A (3), DRS/A (2), DRSLTR (2), POS AM (2), S-3 (2), SEC STAFF LETTER (2), 10-K/A (1), 15-12G (1), 25-NSE (1), 424B4 (1), 424B5 (1), 8-A12B (1), CERT (1), DEFM14A (1), DRS (1), S-1 (1), S-1MEF (1)

  • Latest filingsAnnual report (10-K) Mar 9, 2023
    Quarterly report (10-Q) Aug 2, 2023
    Proxy statement (DEF 14A) Apr 26, 2022
    Latest 8-K (8-K) Sep 8, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
    SEC EDGAROther events
  33. 33
  34. 34
  35. 35
    SEC EDGAROther events
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55